MedPath

Comparison of Effect of Postoperative Cyclosporine A 2% Ophthalmic Emulsion and Betamethasone Eye Drop on Surgical Success of Trabeculectomy Procedure

Phase 2
Completed
Conditions
Glaucoma, Open Angle
Interventions
Registration Number
NCT02114073
Lead Sponsor
Mashhad University of Medical Sciences
Brief Summary

Glaucoma is one of the leading causes of blindness worldwide and trabeculectomy is the most commonly performed operation to slow-down the disease progression. In this study, we compare the effect of topical cyclosporine A and betamethasone eye drops on the postoperative course and surgical success of trabeculectomy.

Detailed Description

Trabeculectomy is still the most popular filtering surgery for glaucomatous patients. In this type of surgery, postoperative care and management is highly important for surgical success. A principle component of postoperative regimen is anti-inflammatory medications. However, corticosteroid eye drops, the most frequently used agents, have some side effects, including raising intraocular pressure.

Cyclosporine A could be an interesting alternative, because not only it has acceptable anti-inflammatory effect and could reduce some ocular surface problems, but also it has minimal direct effect on intraocular pressure. In this study, we will compare the effect of topical cyclosporine A and betamethasone on surgical outcome and postoperative course of trabeculectomy patients.

The study is a prospective study to compare the effect of topical betamethasone and cyclosporine A on postoperative findings of glaucoma patients, undergoing trabeculectomy surgery.

In this study, trabeculectomy patients, who fulfill the study criteria, will be randomized to either study group and follow-up visits will be done in a masked fashion. In each visit, a detailed history taking and eye examination will be done by an examiner unaware of study group. A third party would do data control for patient safety. At the conclusion of the study, the data of the two groups would be compared. All human research ethical codes are strictly respected and the Ethical Committee of the University has an ongoing inspection on all study steps.

We hypothesize that cyclosporine A could provide better inflammation and intraocular pressure control and may enhance surgical success rate. However, our null hypothesis is that the result in study groups will not differ statistically significantly.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • POAG patient with insufficient IOP control on maximal tolerable medical therapy (MTMT), undergoing primary trabeculectomy with MMC augmentation.
Exclusion Criteria
  • Age <20 years
  • History of previous ocular surgery in the same eye;
  • Candidate for combined surgery;
  • Pregnancy;
  • Breast feeding;
  • Monocular subject;
  • Allergy to any topical antiglaucoma medication or cyclosporine

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CyclosporineCyclosporineIn the first postoperative day following a standard, fornix-based trabeculectomy, ophthalmic emulsion of Cyclosporine A, 2%, every 4 hours for the first postoperative week and every 6 hours for the next 3 weeks will be prescribed for the patients.
BetamethasoneBetamethasoneIn the first postoperative day following a standard, fornix-based trabeculectomy, betamethasone eye drop, every 4 hours for the first postoperative week and every 6 hours for the next 3 weeks will be prescribed for the patients.
Primary Outcome Measures
NameTimeMethod
Intraocular Pressure (IOP)Up to 6 months after surgery

Each month following trabeculectomy, intraocular pressure will be measured using Goldmann Applanation Tonometer.

Bleb morphologyUp to 6 months after surgery

Bleb morphology according to IBAGS grading system, based on clinical examination and slit-lamp photography.

Subjective dry eye symptomsUp to 6 months after surgery

Subjective symptoms of dry eye, reported by patients, and gathered using a standardized questionnaire.

Secondary Outcome Measures
NameTimeMethod
Visual acuityUp to 6 months after surgery

LogMAR visual acuity, measured on every postoperative visit.

ComplicationsUp to 6 months after surgery

Any complication observed during study period, reported by patient or examiner.

Surgical success rate6 month after surgery

The surgical success rate of trabeculectomy in each study arm.

Trial Locations

Locations (1)

Khatam Eye Hospital

🇮🇷

Mashhad, Khorasan Razavi, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath